In Section C, individuals will get ABBV-744 and oral navitoclax. In Phase D, members will get ABBV-744 and ruxolitinib. Individuals will obtain treatment right until disease progression or the contributors are not able to tolerate the study drugs. For all flow cytometry experiments, 10,000 cells for every replicate were being https://jaschat999fpz1.blogadvize.com/profile